The United States IVD Raw Materials Market size was valued at USD 1.94 billion in 2025 and is projected to grow from USD 2.12 billion in 2026 to reach USD 4.24 billion by 2034, growing at a CAGR of 9.08% during the forecast period 2026–2034.
The increasing focus on personalized medicine, advancements in diagnostic tools, and the rising prevalence of chronic diseases are key factors driving market growth. Technological advancements, along with rising investments in research and development (R&D), are further bolstering the development of innovative diagnostic solutions for IVD raw materials in the United States.
Download a Free Sample To learn more about this report,
The primary driver of the U.S. IVD raw materials market is the rising prevalence of chronic diseases, including diabetes and cardiovascular conditions. The Centers for Disease Control and Prevention (CDC) reported that approximately 37.3 million Americans had diabetes in 2024, with 1.5 million new cases diagnosed annually. This surge in chronic illnesses demands enhanced diagnostic tools, significantly boosting the need for IVD raw materials, especially for molecular diagnostics and immunoassays. Additionally, the increasing elderly population (projected to reach 77 million by 2030) is driving demand for regular diagnostic testing. Innovations in molecular diagnostics, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), further support the early detection and personalized treatment of diseases.
A significant restraint in the U.S. IVD raw materials market is the high production costs, ultimately transferred to healthcare providers and patients. The stringent regulatory framework of the U.S. Food and Drug Administration (FDA) adds complexity and cost to the manufacturing process. Smaller companies need to work on complying with these regulatory requirements, resulting in delayed product launches and higher operational costs. According to a 2024 report, compliance costs for U.S. IVD manufacturers are increasing by 7% annually, which hinders the expansion of new entrants into the market. High R&D costs and extended timelines for FDA approvals also restrain market growth.
The U.S. IVD raw materials market presents substantial opportunities due to increased R&D investments from pharmaceutical and biotechnology companies. In 2024, the National Institutes of Health (NIH) allocated over USD 41 billion for healthcare research, with significant funding for diagnostic innovations. These investments enable the development of advanced diagnostic tools, particularly in molecular diagnostics and immunochemistry. The rise of precision medicine and the growing adoption of next-generation diagnostic technologies, such as liquid biopsies and immunoassays, offer lucrative opportunities for companies to enhance their product portfolios and gain a competitive edge.
Antibody dominates the product type segment and is expected to grow at a CAGR of 11.9% over the forecast period. Antibodies are critical to the U.S. IVD raw materials market, primarily used in immunoassays and molecular diagnostics. The demand for monoclonal and polyclonal antibodies is rising due to the increasing prevalence of cancer and autoimmune diseases. Hospitals and diagnostic labs are expanding their use of antibody-based tests, particularly for cancer diagnostics such as immunohistochemistry (IHC), driving growth in this segment.
Request Customizationto receive a tailored report.
Immunochemistry dominates the technology segment and is expected to grow at a CAGR of 12.3% through 2033. Immunochemistry technologies are widely adopted in point-of-care testing and home diagnostics in the U.S. Their growing popularity is attributed to advancements in automated platforms and reagent systems that reduce diagnostic time and improve accuracy. The high demand for chemiluminescence immunoassays (CLIA) in detecting biomarkers with precision is expected to sustain the segment's growth throughout the forecast period.
Pharmaceutical and biotechnological companies dominate the end-user segment and is expected to grow at a CAGR of 12.9%. Pharmaceutical and biotechnological companies are significant end-users of IVD raw materials in the U.S., where the push for personalized medicine is accelerating collaborations between diagnostic manufacturers and pharmaceutical firms. This trend is particularly robust in immuno-oncology, where the focus on biomarker-driven drug development is expected to boost demand for high-quality IVD materials in clinical trials.
Speak to an Analystto discuss market opportunities.
The United States IVD raw materials market’s advanced healthcare infrastructure, high investment in biotechnology, and increasing prevalence of chronic diseases are key drivers of market growth. Moreover, the U.S. government’s focus on expanding diagnostic capabilities through personalized medicine and early disease detection has accelerated the demand for high-quality IVD raw materials. The U.S. leads the global market in innovation and development of diagnostic technologies, ensuring a steady demand for key raw materials like antibodies, antigens, and enzymes.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
N95 Masks Market Size, Share, Growth, Analysis, Report, 2034
Digital X-Ray Devices Market Size, Share, Growth, Analysis, 2034
Contrast Enhanced Ultrasound Market Size, Share, Growth, 2034
Active Wound Care Market Size, Share, Growth, Forecast, 2034
Perfusion System Market Size, Share, Growth, Forecast, 2034
Medical Digital Imaging System Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com